Quote | Prometheus Biosciences Inc. (NASDAQ:RXDX)
Last: | $199.92 |
---|---|
Change Percent: | 0.12% |
Open: | $199.68 |
Close: | $199.92 |
High: | $199.98 |
Low: | $199.6 |
Volume: | 1,860,653 |
Last Trade Date Time: | 06/15/2023 03:00:00 am |
News | Prometheus Biosciences Inc. (NASDAQ:RXDX)
2023-05-31 08:54:58 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a globally synchronized world, there are big opportunities across sectors. This has intensified competition as companies look to grab a share of the pie. It eventually boils down to the su...
2023-05-30 22:04:25 ET Summary Merck has agreed to acquire clinical-stage biotech company Prometheus Biosciences for $200 per share in cash, with the deal expected to close late in Q2 or early in Q3. The acquisition will advance Merck's presence in immunology, focusing on late-sta...
Message Board Posts | Prometheus Biosciences Inc. (NASDAQ:RXDX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $RXDX News Article - These 3 Nasdaq Stocks Are on Fire Today: Here's Why | whytestocks | investorshangout | 04/17/2023 6:05:49 PM |
whytestocks: $RXDX News Article - Why Shares of Prometheus Biosciences Are Soaring Monday | whytestocks | investorshangout | 04/17/2023 4:25:47 PM |
whytestocks: $RXDX News Article - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of | whytestocks | investorshangout | 04/17/2023 3:45:48 PM |
znewcar1: $RXDX 22% v4,4M c117.21 f41,9M H117.73 YL94.87 then morning pushed | znewcar1 | investorshangout | 12/08/2022 9:53:54 PM |
whytestocks: $RXDX News Article - Biotechs Race for New Treatments as Breast Cancer Therapeutics Mar | whytestocks | investorshangout | 12/08/2022 3:35:50 PM |
News, Short Squeeze, Breakout and More Instantly...
Prometheus Biosciences Inc. Company Name:
RXDX Stock Symbol:
NASDAQ Market:
NEW YORK, NY / ACCESSWIRE / May 25, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Prometheus Biosciences, Inc. (NASDAQ:RXDX...
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated disease...